A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of Baricitinib in Patients With Moderate-to-Severe Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Baricitinib (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 22 Jan 2016 Primary endpoint of percentage of North American patients achieving PASI-75 at week 12 has been met, according to results published in the British Journal of Dermatology.
- 22 Jan 2016 Results published in the British Journal of Dermatology
- 07 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.